Assessment of a Patient-Centric Web Application Tool for Potential Adverse Events of Oral Corticosteroids

Author(s)

Valliant S1, Sadatsafavi M2, Picton-March A3, Barazetti-Scott J3, Chase K4, Kerr W5, Alfonso-Cristancho R1
1GSK, Collegeville, PA, USA, 2NAPTIA Consultation, North Vancouver, BC, Canada, 3Human8, Manchester, Greater Manchester, UK, 4Human8, London, Greater London, UK, 5GSK, Brentford, Middlesex, UK

OBJECTIVES: Oral corticosteroids (OCS) are frequently used to treat severe asthma and other chronic diseases, despite the potential risk of adverse effects even with short treatment courses. Tools that increase patient awareness through a shared decision-making process may help reduce avoidable OCS exposure. The objective of this study was to assess the design and usability of a web application tool to educate patients on the risks associated with OCS use.

METHODS: The tool was assessed using an online quantitative survey and interviews with patients with asthma in the USA. Users input OCS usage to summarize their relative and absolute risk of specific outcomes based on results from a separate study. Inclusion criteria: aged 18–65 years, asthma diagnosis ≥2 years, ≥1 exacerbation within previous 12 months, on maintenance inhaled therapy. Patients were questioned on tool design and ease of use, interpretability of information provided, and tool improvements.

RESULTS: Overall, 26 patients completed the online survey and 12 participated in interviews (n=6 for current and previous OCS users, respectively). Tool design: 77% of participants liked the overall look although only 46% agreed with color use, 81% found clear and concise display of information. Information provided: 88% found it easy to understand, 85% found it trustworthy and credible, 81% said it was new to them, while chart/table data presentation was most preferred overall (24% ranked first). Improvements: 73% of participants said they were likely to recommend the tool to a friend using OCS. Interview responses included greater clarity on the tool’s purpose, more guidance on utilizing the results and simpler data statistics.

CONCLUSIONS: Most patients found the tool simple to use and provided valuable and trustworthy information while highlighting prior unawareness of OCS risk. More nuanced risk scoring based on a variety of patient characteristics might improve utility.

FUNDING: GSK (Study 220116)

Conference/Value in Health Info

2024-05, ISPOR 2024, Atlanta, GA, USA

Value in Health, Volume 27, Issue 6, S1 (June 2024)

Code

MT48

Topic

Medical Technologies

Disease

No Additional Disease & Conditions/Specialized Treatment Areas, Respiratory-Related Disorders (Allergy, Asthma, Smoking, Other Respiratory)

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×